2012
12O_PR Independent Blinded Validation of the Genomic Index of Sensitivity to Endocrine Therapy (Set)
Karn T, Hatzis C, Symmans W, Pusztai L, Ruckhäberle E, Schmidt M, Müller V, Holtrich U, Rody A, Kaufmann M. 12O_PR Independent Blinded Validation of the Genomic Index of Sensitivity to Endocrine Therapy (Set). Annals Of Oncology 2012, 23: ii18. DOI: 10.1016/s0923-7534(19)65684-x.Peer-Reviewed Original ResearchEndocrine therapyPositive patientsPrognostic valueTumor sizeER-positive primary breast cancerPositive primary breast cancerAdjuvant endocrine therapyNegative PgR statusNode-negative cohortPure prognostic valueNode-negative patientsStepwise Cox regressionER-positive patientsPrimary breast cancerBest independent predictorPgR statusAdjuvant treatmentRetrospective cohortIndependent predictorsLymph nodesNegative cohortSurvival benefitCox regressionClinical associationsHER2 status
2011
First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations
Iwamoto T, Lee JS, Bianchini G, Hubbard RE, Young E, Matsuoka J, Kim SB, Symmans WF, Hortobagyi GN, Pusztai L. First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations. Breast Cancer Research And Treatment 2011, 130: 155. PMID: 21833625, DOI: 10.1007/s10549-011-1706-9.Peer-Reviewed Original ResearchConceptsLong-term survivalPrognostic gene signatureClinical variablesChemotherapy responseGenomic prognostic markersPrognostic markerPredictive valueKaplan-Meir survival curvesSignificant independent predictive valuePathologic complete responseProgression-free survivalLong-term followIndependent predictive valueSame patient cohortReceiver operator characteristic curveOperator characteristic curveOverall survivalPreoperative chemotherapyComplete responseNodal statusIndependent prognosticClinicopathological variablesPatient populationHER2 statusPatient cohortArtificial neural network analysis of circulating tumor cells in metastatic breast cancer patients
Giordano A, Giuliano M, De Laurentiis M, Eleuteri A, Iorio F, Tagliaferri R, Hortobagyi GN, Pusztai L, De Placido S, Hess K, Cristofanilli M, Reuben JM. Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. Breast Cancer Research And Treatment 2011, 129: 451-458. PMID: 21710134, DOI: 10.1007/s10549-011-1645-5.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBreast NeoplasmsFemaleHumansImmunohistochemistryKaplan-Meier EstimateLinear ModelsMiddle AgedNeoplastic Cells, CirculatingNeural Networks, ComputerPrognosisProportional Hazards ModelsReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneRetrospective StudiesRisk AssessmentRisk FactorsSurvival RateTexasTime FactorsConceptsMetastatic breast cancer patientsRisk of deathBreast cancer patientsCTC countMBC patientsPrognostic effectCancer patientsTumor subtypesTumor cellsMD Anderson Cancer CenterConsecutive MBC patientsTriple-negative MBCMetastatic disease sitesAnderson Cancer CenterTumor molecular subtypeNumber of CTCsMolecular tumor subtypesVisceral metastasesOverall survivalCancer CenterHER2 statusProgesterone receptorMolecular subtypesTherapy typePrognostic tool
2010
Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer
Iwamoto T, Bianchini G, Qi Y, Cristofanilli M, Lucci A, Woodward WA, Reuben JM, Matsuoka J, Gong Y, Krishnamurthy S, Valero V, Hortobagyi GN, Robertson F, Symmans WF, Pusztai L, Ueno NT. Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Research And Treatment 2010, 125: 785-795. PMID: 21153052, PMCID: PMC4109066, DOI: 10.1007/s10549-010-1280-6.Peer-Reviewed Original ResearchConceptsInflammatory breast cancerClinical subtypesBreast cancerNon-IBC patientsCase-control studyDistinct clinical subtypesDifferent molecular subtypesNon-IBC tumorsSignificant differencesNon-IBC specimensImmune system-related pathwaysLipid metabolism-related pathwaysHER2 statusReceptor phenotypeMetabolism-related pathwaysMolecular subtypesIBC tumorsSurvival curvesSubtypesTumor samplesHormone receptorsCancerPatientsT-testHER2
2009
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer
Liedtke C, Broglio K, Moulder S, Hsu L, Kau S, Symmans WF, Albarracin C, Meric-Bernstam F, Woodward W, Theriault RL, Kiesel L, Hortobagyi GN, Pusztai L, Gonzalez-Angulo AM. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Annals Of Oncology 2009, 20: 1953-1958. PMID: 19596702, PMCID: PMC2791352, DOI: 10.1093/annonc/mdp263.Peer-Reviewed Original ResearchConceptsTriple receptor-negative breast cancerRecurrent breast cancerPost-recurrence survivalProgesterone receptorRecurrent tumorsBreast cancerEstrogen receptorDiscordant casesBetter post-recurrence survivalReceptor-positive breast cancerReceptor-negative breast cancerDiscordant receptor statusHormone receptor measurementsPrognostic impactReceptor statusUnfavorable survivalPathological parametersHER2 statusPoor survivalReceptor measurementsIHC scorePatientsClinical phenotypeSuboptimal reproducibilityCancer
2008
Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers
Mazouni C, Arun B, André F, Ayers M, Krishnamurthy S, Wang B, Hortobagyi GN, Buzdar AU, Pusztai L. Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers. British Journal Of Cancer 2008, 99: 68-71. PMID: 18560403, PMCID: PMC2453019, DOI: 10.1038/sj.bjc.6604443.Peer-Reviewed Original ResearchConceptsCollagen IV levelsHealthy womenCancer patientsBreast cancerPreoperative chemotherapySerum levelsCollagen IVBaseline serum levelsSerum collagen IVPrimary breast cancerBreast cancer patientsSera of patientsMarkers of angiogenesisSandwich enzyme-linked immunoassayEnzyme-linked immunoassayCollagen IV concentrationVascular basement membraneClinical stageHER2 statusHealthy controlsSignificant further increaseHealthy volunteersPatientsChemotherapyStage II
2007
HER2 expression and efficacy of preoperative paclitaxel and 5-fluorouracil, cyclophosphamide, doxorubicin chemotherapy in breast cancer
Pusztai L, Andre F, Mazouni C, Liedtke C, Kau S, Frye D, Green M, Gonzalez-Angulo A, Symmans W, Hortobagyi G. HER2 expression and efficacy of preoperative paclitaxel and 5-fluorouracil, cyclophosphamide, doxorubicin chemotherapy in breast cancer. Journal Of Clinical Oncology 2007, 25: 548-548. DOI: 10.1200/jco.2007.25.18_suppl.548.Peer-Reviewed Original ResearchPathologic complete responseHER2 overexpressionPCR rateBreast cancerER- cancersHER2- diseaseHER2 expressionRelapse-free survival rateER-negative statusWeekly paclitaxel regimenMicrotubule associated protein tauHigh nuclear gradePaclitaxel regimenPreoperative paclitaxelFAC chemotherapyPreoperative chemotherapyComplete responseHER2 tumorsHER2 statusDoxorubicin chemotherapyNuclear gradeRetrospective analysisPatientsTaxane sensitivitySurvival rateStandardizing Slide-Based Assays in Breast Cancer: Hormone Receptors, HER2, and Sentinel Lymph Nodes
Ross JS, Symmans WF, Pusztai L, Hortobagyi GN. Standardizing Slide-Based Assays in Breast Cancer: Hormone Receptors, HER2, and Sentinel Lymph Nodes. Clinical Cancer Research 2007, 13: 2831-2835. PMID: 17504980, DOI: 10.1158/1078-0432.ccr-06-2522.Peer-Reviewed Original ResearchConceptsReceptor statusClinical practiceHormone receptor statusProgesterone receptor statusBreast cancer careBreast cancer patientsSentinel lymph nodesDaily clinical practiceCurrent clinical practiceSignificant unmet needFalse-positive result ratesLymph nodesCancer careCancer patientsHER2 statusBreast cancerEstrogen receptorImmunohistochemistry techniquesUnmet needResult rateHormone receptorsPreanalytic conditionsNovel diagnosticsCareReceptors